Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 37 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Colorectal cancer Gastrointestinal Cancer , Oncology 2017 View  |  Download
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy Atezolizumab (Tecentriq; MPDL3280A) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab for adjuvant treatment of muscle-invasive bladder cancer Atezolizumab (Tecentriq; MPDL3280A) Bladder cancer Urological Cancer 2024 View  |  Download
Atezolizumab for adjuvant treatment of squamous cell carcinoma of the head and neck Atezolizumab (Tecentriq; MPDL3280A) Head and neck cancer Head and Neck Cancer 2021 View  |  Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant Atezolizumab (Tecentriq; MPDL3280A) Bladder cancer Urological Cancer 2019 View  |  Download
Atezolizumab for previously untreated recurrent or advanced non-small cell lung cancer unsuitable for platinum-doublet chemotherapy Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Atezolizumab for resected non-small cell lung cancer - adjuvant Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Atezolizumab for stage IV non-squamous or squamous non-small cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Atezolizumab in addition to Carboplatin or Cisplatin and Pemetrexed for Stage IV non-squamous non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Cisplatin (Platinol) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Atezolizumab in addition to chemotherapy for small cell lung cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2018 View  |  Download
1 2 3 4
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications